Literature DB >> 26968946

HLA-G and classical HLA class I expression in primary colorectal cancer and associated liver metastases.

Marloes Swets1, Marion H König2, Anniek Zaalberg2, Neeltje G Dekker-Ensink2, Hans Gelderblom3, Cornelis J H van de Velde2, Peter J van den Elsen4, Peter J K Kuppen5.   

Abstract

De novo expression of HLA-G has been demonstrated in colorectal cancer. HLA-G, amongst others, inhibits natural killer cell function, contributing to host immune defense evasion. Another mechanism to escape anti-tumor immunity is loss of HLA class I. Therefore, we determined HLA-G and HLA class I expression on primary colorectal tumors and associated liver metastases, in order to get insight in the metastasizing process regarding escaping anti-tumor immunity. HLA-G expression was evaluated using three mAbs; 4H84, MEM-G/1 and MEM-G/2. In total 81 colorectal cancer patients were evaluated. Formalin-fixed paraffin-embedded tissue sections of primary tumors and associated liver metastases, were immunohistochemically stained. A concordance between expression or loss/downregulation in the primary tumor and associated liver metastasis regarding HLA class I expression was observed in 80% of the cases. In contrast with the hypothesis of escaping NK cell-killing, we demonstrated for each HLA-G detecting mAbs used in this study, that the majority of the primary tumors that positively stained for HLA-G did not express HLA-G in the associated liver metastasis. Furthermore, we revealed the existence of non-specific binding and in addition we found that the different epitopes of HLA-G detected by 4H84, MEM-G/1 and MEM-G/2 mAbs were expressed differentially in colorectal tumor tissues.
Copyright © 2016 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Colorectal cancer; HLA class I; HLA-G; Liver metastases

Mesh:

Substances:

Year:  2016        PMID: 26968946     DOI: 10.1016/j.humimm.2016.03.001

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  17 in total

1.  HLA-G expression in gastric carcinoma: clinicopathological correlations and prognostic impact.

Authors:  Giuseppe Murdaca; Paola Calamaro; Francesca Lantieri; Simona Pigozzi; Luca Mastracci; Federica Grillo; Ottavia Magnani; Paola Ceppa; Francesco Puppo; Roberto Fiocca
Journal:  Virchows Arch       Date:  2018-05-29       Impact factor: 4.064

2.  HLA-G as a prognostic marker in stage II/III colorectal cancer: not quite there yet.

Authors:  Federica Grillo; Luca Mastracci; Alessandro Gambella; Stefano Scabini; Gabriele Zoppoli; Annalisa De Silvestri; Simona Pigozzi; Michele Paudice; Michela Campora; Roberto Fiocca
Journal:  Histochem Cell Biol       Date:  2022-07-28       Impact factor: 2.531

3.  A collection of annotated and harmonized human breast cancer transcriptome datasets, including immunologic classification.

Authors:  Lance D Miller; Davide Bedognetti; Wouter Hendrickx; Jessica Roelands; Julie Decock; Sabri Boughorbel; Darawan Rinchai; Cristina Maccalli; Michele Ceccarelli; Michael Black; Cris Print; Jeff Chou; Scott Presnell; Charlie Quinn; Puthen Jithesh; Najeeb Syed; Salha B J Al Bader; Shahinaz Bedri; Ena Wang; Francesco M Marincola; Damien Chaussabel; Peter Kuppen
Journal:  F1000Res       Date:  2017-03-20

Review 4.  Immunogenomic Classification of Colorectal Cancer and Therapeutic Implications.

Authors:  Jessica Roelands; Peter J K Kuppen; Louis Vermeulen; Cristina Maccalli; Julie Decock; Ena Wang; Francesco M Marincola; Davide Bedognetti; Wouter Hendrickx
Journal:  Int J Mol Sci       Date:  2017-10-24       Impact factor: 5.923

Review 5.  Heterogeneity of HLA-G Expression in Cancers: Facing the Challenges.

Authors:  Aifen Lin; Wei-Hua Yan
Journal:  Front Immunol       Date:  2018-09-27       Impact factor: 7.561

Review 6.  The Role of the Lymphocyte Functional Crosstalk and Regulation in the Context of Checkpoint Inhibitor Treatment-Review.

Authors:  Barbara Seliger
Journal:  Front Immunol       Date:  2019-09-06       Impact factor: 7.561

Review 7.  The Immunogenicity of Colorectal Cancer in Relation to Tumor Development and Treatment.

Authors:  Natasja L de Vries; Marloes Swets; Alexander L Vahrmeijer; Marianne Hokland; Peter J K Kuppen
Journal:  Int J Mol Sci       Date:  2016-06-29       Impact factor: 5.923

8.  Characterization of circulating T-, NK-, and NKT cell subsets in patients with colorectal cancer: the peripheral blood immune cell profile.

Authors:  Daniëlle Krijgsman; Natasja L de Vries; Anni Skovbo; Morten N Andersen; Marloes Swets; Esther Bastiaannet; Alexander L Vahrmeijer; Cornelis J H van de Velde; Mirjam H M Heemskerk; Marianne Hokland; Peter J K Kuppen
Journal:  Cancer Immunol Immunother       Date:  2019-05-03       Impact factor: 6.968

9.  HLA-G and HLA-F protein isoform expression in breast cancer patients receiving neoadjuvant treatment.

Authors:  Franziska M Wuerfel; Hanna Huebner; Lothar Häberle; Paul Gass; Alexander Hein; Sebastian M Jud; Carolin C Hack; Marius Wunderle; Rüdiger Schulz-Wendtland; Ramona Erber; Arndt Hartmann; Arif B Ekici; Matthias W Beckmann; Peter A Fasching; Matthias Ruebner
Journal:  Sci Rep       Date:  2020-09-25       Impact factor: 4.379

Review 10.  HLA-G/ILTs Targeted Solid Cancer Immunotherapy: Opportunities and Challenges.

Authors:  Aifen Lin; Wei-Hua Yan
Journal:  Front Immunol       Date:  2021-06-30       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.